Immune efficacy of oprH chitosan nanoparticle DNA vaccine against Pseudomonas aeruginosa

Document Type : Full paper (Original article)

Authors

1 Department of Bioengineering, Faculty of Food and Bioengineering, Henan University of Science and Technology, Luoyang, China

2 MSc Student in Microbiology, Department of Bioengineering, Faculty of Food and Bioengineering, Henan University of Science and Technology, Luoyang, China

3 MSc Student in Food Microbiology, Henan Engineering Research Center of Food Microbiology, Faculty of Food and Bioengineering, Henan University of Science and Technology, Luoyang, China

Abstract

Background: Pseudomonas aeruginosa is a zoonotic pathogen that poses a threat to human and animal health. However, no vaccine exists for controlling this bacterium. Aims: This study aimed to evaluate the immune efficacy of a chitosan nanoparticle DNA vaccine of the oprH gene from P. aeruginosa. Methods: The naked DNA vaccine based on the oprH gene of P. aeruginosa was constructed. Then, the chitosan nanoparticle DNA vaccine of the oprH gene was prepared and the shape, size, encapsulation efficiency, stability, and ability of anti-DNA enzyme degradation were detected. Chickens were divided into five groups, namely the naked DNA vaccine group (poprH group), chitosan nanoparticle DNA vaccine group (CpoprH group), outer membrane protein vaccine group (OMP group), inactive vaccine group, and PBS group. After being vaccinated with corresponding vaccines, the levels of serum antibodies, lymphocyte proliferation assays, interferon-γ (IFN-γ), interleukin-2 (IL-2), and interleukin-4 (IL-4) concentrations were detected. Groups of chickens were challenged with live virulent P. aeruginosa 2 weeks after the last vaccination and the survival numbers were counted until day 15 post challenge. Then, the protective rates were calculated. Results: The particle size of the chitosan nanoparticle DNA vaccine was approximately 200 nm and close to spherical; the encapsulation efficiency was 95.88%, and it could effectively resist degradation by DNase. Following vaccination, serum antibodies, stimulation index (SI) value, and concentrations of IFN-γ, IL-2, and IL-4 in chickens immunized with the chitosan nanoparticle DNA vaccine were significantly higher than those that were vaccinated with the naked DNA vaccine (P<0.05). The protective rates of poprH, CoprH, OMP vaccine, and inactive vaccine groups were 55%, 75%, 75%, and 90%, respectively. Conclusion: Chitosan could significantly enhance the immune response and protection provided by the naked DNA vaccine of the oprH gene.

Keywords

Main Subjects

References

Abianeh, HS; Nazarian, S; Sadeghi, D; Razgi, ASH and Samarin, MZ (2023). PLGA nanoparticles containing intimin-flagellin fusion protein for E. coli O157:H7 nano-vaccine. J. Immunol. Methods. 520: 113517.
Bai, J; Zhang, Z; Lian, P; Wang, X and Qiao, J (2022). Investigations of melatonin influences on mink resistances to Pseudomonas aeruginosa. Emerg. Anim. Spec., 5: 100020.
Barbey, C; Su, J; Billmeier, M; Stefan, N; Bester, R; Carnell, G; Temperton, N; Heeney, J; Protzer, U; Breunig, M; Wagner, R and Peterhoff, D (2023). Immunogenicity of a silica nanoparticle-based SARS-CoV-2 vaccine in mice. Eur. Pharm. Biopharm., 192: 41-45.
Beg, AZ; Farhat, N and Khan, AU (2021). Designing multi-epitope vaccine candidates against functional amyloids in Pseudomonas aeruginosa through immunoinformatic and structural bioinformatics approach. Infect. Gen. Evol., 93: 104982.
Eusébio, D; Neves, AR; Costa, D; Biswas, S; Alves, G; Cui, Z and Sousa, Â (2021). Methods to improve the immunogenicity of plasmid DNA vaccines. Drug. Discov. Today. 26: 2575-2592.
Gong, Q; Li, Y; Zhai, W and Niu, M (2022). Immune responses and protective efficacy of a trivalent combination DNA vaccine based on oprL, oprF and flgE genes of Pseudomonas aeruginosa. Vet. Med-Czech., 67: 1-9.
Gong, Q; Ruan, MD; Niu, MF and Qin, CL (2021). Immune efficacy of different immunization doses of divalent combination DNA vaccine pOPRL+pOPRF of Pseudomonas aeruginosa. J. Vet. Med. Sci., 83: 1959-1964.
Gong, Q; Ruan, MD; Niu, MF; Qin, CL; Hou, Y and Guo, JZ (2018). Immune efficacy of DNA vaccines based on oprL and oprF genes of Pseudomonas aeruginosa in chickens. Poultry Sci., 97: 4219-4227.
Huo, X; Tang, L; Liu, Q; Zhu, W; Zhang, J; Hu, M; Zhao, F; Wang, P; Yuan, G; Yang, C and Su, J (2023). Oral pcDNA3.1-VP4/VP56-FlaC DNA vaccine encapsulated by chitosan/sodium alginate nanoparticles confers remarkable protection against GCRV infection in grass carp. Aquaculture. 577: 739996.
Jiang, B; Luo, Y; Yan, N; Shen, Z; Li, W; Hou, C; Xiao, L; Ma, C; Zhang, L; Chen, Y; Cheng, X; Lian, M; Ji, C; Zhu, Z and Wang, Z (2023). An X-ray inactivated vaccine against Pseudomonas aeruginosa Keratitis in mice. Vaccine. 41: 4700-4709.
Khatami, SH; Karami, S; Siahkouhi, HR; Taheri-Anganeh, M; Fathi, J; Ghadim, MBA; Taghvimi, S; Shabaninejad, Z; Tondro, G; Karami, N; Dolatshah, L; Fard, ES; Movahedpour, A and Darvishi, MH (2022). Aptamer-based biosensors for Pseudomonas aeruginosa detection. Mol. Cell. Probe., 66: 101865.
Korpi, F; Irajian, G; Forouhi, F and Mohammadian, T (2023). A chimeric vaccine targeting Pseudomonas aeruginosa virulence factors protects mice against lethal infection. Microb. Pathog., 178: 106033.
Mao, L; Chen, Z; Wang, Y and Chen, C (2021). Design and application of nanoparticles as vaccine adjuvants against human corona virus infection. J. Inorg. Biochem., 219: 111454.
Mo, J; Si, H; Liu, S; Zeng, Q; Cai, M; Liu, Z; Zhang, J; Fang, J and Zhang, J (2023). Effect of the pseudomonas metabolites HQNO on the Toxoplasma gondii RH strain in vitro and in vivo. Int. J. Parasitol-Drug. 21: 74-80.
Parra-Millán, R; Jiménez-Mejías, ME; Ayerbe-Algaba, R;
Domínguez-Herrera, J; Díaz, C; Palacio, JP; Pachón, J and Smani, Y (2022). Impact of the immune response modification by lysophosphatidylcholine in the efficacy of antibiotic therapy of experimental models of peritoneal sepsis and pneumonia by Pseudomonas aeruginosa: LPC therapeutic effect in combined therapy. Enferm. Infec. Micr. Cl., 40: 14-21.
Santos, ED; Jiménez, CM; Río-Carbajo, L and Vidal-Cortés, P (2022). Treatment of severe multi-drug resistant Pseudomonas aeruginosa infections. Med. Intensiva., 46: 508-520.
Sathe, N; Beech, P; Croft, L; Suphiogluc, C; Kapat, A and Athan, E (2023). Pseudomonas aeruginosa: Infections and novel approaches to treatment “Knowing the enemy” the threat of Pseudomonas aeruginosa and exploring novel approaches to treatment. Infect. Med., 2: 178-194.
Shi, D; Fan, B; Sun, B; Zhou, J; Zhao, Y; Guo, R; Ma, Z; Song, T; Fan, H; Li, J; Li, L and Li, B (2022). LDH nanoparticle adjuvant subunit vaccine induces an effective immune response for porcine epidemic diarrhea virus. Virology. 565: 58-64.
Xiang, Y; Yan, L; Zheng, X; Li, L; Liu, P and Cao, W (2020). Rapid detection of Pseudomonas aeruginosa by cross priming amplification. J. Integr. Agr., 19: 2523-2529.
Yang, H; Liu, A; Ma, F; Gao, X; Wang, K and Wang, Y (2024). Establishment of portable Pseudomonas aeruginosa detection platform based on one-tube CRISPR/Cas12a combined with recombinase polymerase amplification technology. Clin. Chim. Acta., 554: 117760.
Yu, N; Zeng, W; Xiong, Z and Liu, Z (2022). A high efficacy DNA vaccine against Tilapia lake virus in Nile tilapia (Oreochromis niloticus). Aquacult. Re., 24: 101166.
Zhang, Y; Tian, L; Zhao, X; Jiang, XF; Qin, J; Wang, Y and Yu, X (2024). Enhanced protective efficacy of an OprF/PcrV bivalent DNA vaccine against Pseudomonas aeruginosa using a hydrogel delivery system. Biomed. Pharmacother., 172: 116264.

Files

Share

How to cite

Statistics